Biotech Earnings Preview: Mixed Results Send Stocks on Divergent Paths
Nuvation Bio and Sarepta shares tumble on disappointing preliminary results while Adaptive Biotechnologies surges on strong revenue beat.
Nuvation Bio and Sarepta shares tumble on disappointing preliminary results while Adaptive Biotechnologies surges on strong revenue beat.
Clear Street keeps $12 price target on NUVB after NUV-1511 discontinuation, citing blockbuster potential for IBTROZI and safusidenib programs.
Nuvation Bio shares jump 49% Wed. after strong Ibtrozi results and analyst upgrades, signaling growth potential in biotech and cancer treatments.
Jefferies issued a Buy rating on Nuvation Bio with a $10 price target, citing its FDA-approved lead drug, strong pipeline potential, and cash reserves extending into 2028.